{"id":"sar153191-regn88","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":{"chemblId":"CHEMBL2108730","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, SAR153191 prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation, leading to enhanced anti-tumor immune responses.","oneSentence":"SAR153191 is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:29.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT02991469","phase":"PHASE2","title":"A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2018-08-09","conditions":"Juvenile Idiopathic Arthritis","enrollment":51},{"nctId":"NCT05125016","phase":"PHASE1, PHASE2","title":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-11-30","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":370},{"nctId":"NCT06787612","phase":"PHASE2","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-05-28","conditions":"Ovarian Cancer","enrollment":220},{"nctId":"NCT03564340","phase":"PHASE1, PHASE2","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-05-21","conditions":"Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer","enrollment":890},{"nctId":"NCT04327388","phase":"PHASE3","title":"Sarilumab COVID-19","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-03-28","conditions":"Corona Virus Infection","enrollment":420},{"nctId":"NCT03378219","phase":"","title":"An Observational Study on Sarilumab-exposed Pregnancies","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-18","conditions":"Rheumatoid Arthritis -Exposure During Pregnancy","enrollment":113},{"nctId":"NCT02776735","phase":"PHASE2","title":"An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-06","conditions":"Juvenile Idiopathic Arthritis","enrollment":102},{"nctId":"NCT03600818","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-10-09","conditions":"Polymyalgia Rheumatica","enrollment":118},{"nctId":"NCT03449758","phase":"PHASE4","title":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-05","conditions":"Rheumatoid Arthritis","enrollment":84},{"nctId":"NCT02332590","phase":"PHASE3","title":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-28","conditions":"Rheumatoid Arthritis","enrollment":369},{"nctId":"NCT01146652","phase":"PHASE3","title":"Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06-21","conditions":"Rheumatoid Arthritis","enrollment":2023},{"nctId":"NCT04315298","phase":"PHASE2, PHASE3","title":"Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-03-18","conditions":"COVID-19","enrollment":1912},{"nctId":"NCT02373202","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-02","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT02293902","phase":"PHASE3","title":"A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-11","conditions":"Rheumatoid Arthritis","enrollment":243},{"nctId":"NCT01217814","phase":"PHASE2","title":"Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT01709578","phase":"PHASE3","title":"To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":546},{"nctId":"NCT01061723","phase":"PHASE2","title":"Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Ankylosing Spondylitis","enrollment":301},{"nctId":"NCT01764997","phase":"PHASE3","title":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","status":"TERMINATED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":776},{"nctId":"NCT01061736","phase":"PHASE2, PHASE3","title":"Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-03","conditions":"Rheumatoid Arthritis","enrollment":1675},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT01118728","phase":"PHASE2","title":"Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-06","conditions":"Ankylosing Spondylitis","enrollment":223},{"nctId":"NCT02121210","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-06","conditions":"Rheumatoid Arthritis","enrollment":132},{"nctId":"NCT02057250","phase":"PHASE3","title":"To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"RA","enrollment":217},{"nctId":"NCT01900431","phase":"PHASE2","title":"Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-10","conditions":"Uveitis","enrollment":58},{"nctId":"NCT02017639","phase":"PHASE1","title":"Sarilumab Effect on the Pharmacokinetics of Simvastatin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":19},{"nctId":"NCT02404558","phase":"PHASE1","title":"Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-05","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT02097524","phase":"PHASE1","title":"Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-03","conditions":"Rheumatoid Arthritis","enrollment":105},{"nctId":"NCT01850680","phase":"PHASE1","title":"Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":61},{"nctId":"NCT01011959","phase":"PHASE1","title":"A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2008-12","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT01026519","phase":"PHASE1","title":"A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT01055899","phase":"PHASE1","title":"Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2008-07","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT01328522","phase":"PHASE1","title":"Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SAR153191 (REGN88)","genericName":"SAR153191 (REGN88)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SAR153191 (REGN88) is an interleukin-6 receptor alpha subunit antagonist, classified as an antibody antagonist. It is being studied in clinical trials for various conditions, including Ankylosing Spondylitis, COVID-19, and Recurrent Ovarian Cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}